Baidu
map

联合用药治疗HIV和利什曼病共感染

2019-01-27 MedSci MedSci原创

内脏利什曼病与人类免疫缺陷病毒(HIV)共感染已经是一个日益严重的问题。这种类型的共感染需要特殊的疾病管理。目前,世界卫生组织推荐AmBisome单药治疗。然而,研究人员现已表明,AmBisome和米替福新的联合治疗更有效。

内脏利什曼病与人类免疫缺陷病毒(HIV)共感染已经是一个日益严重的问题。这种类型的共感染需要特殊的疾病管理。目前,世界卫生组织推荐AmBisome单药治疗。然而,研究人员现已表明,AmBisome和米替福新的联合治疗更有效。

HIV的感染可以增加利什曼病的发病率和复发率,并且也会加重其严重程度。在埃塞俄比亚西北部,利什曼病患者的HIV的感染率达20%-40%。研究显示,每公斤30毫克的AmBisome在43-70%的艾滋病病毒感染者中有效,但是患者的死亡率仍然在攀升。

在该研究中,瑞士SéverineBlesson博士在埃塞俄比亚西北部的一个治疗中心开展一项富含同情心的临床试验方案,将AmBiosome和米替福新联合使用。该小组分析了在29天和58天寄生虫清除的效力。在536名内脏利什曼病患者中,81名HIV阳性,59名参加了试验。其中,19例接受了AmBiosome单药治疗的标准治疗,39例接受了联合治疗。

29天后,AmBisome的有效率为50%,联合治疗的有效率为67%。在第58天,单药治疗为55%,组合为88%。另外,没有发现关于联合治疗的安全性问题。

研究人员表示:"这项试验结果即使令人鼓舞,强烈提示了需要改变HIV和利什曼病共感染患者治疗方案。然而,这一联用方案也无法毫无保留地推广到其他环境。"

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951237, encodeId=c672195123eae, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Nov 13 04:23:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066326, encodeId=5d852066326ad, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Fri Aug 02 13:23:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514289, encodeId=ee87151428978, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Tue Jan 29 12:23:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359389, encodeId=5b5835938971, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Jan 27 22:26:06 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951237, encodeId=c672195123eae, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Nov 13 04:23:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066326, encodeId=5d852066326ad, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Fri Aug 02 13:23:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514289, encodeId=ee87151428978, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Tue Jan 29 12:23:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359389, encodeId=5b5835938971, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Jan 27 22:26:06 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1951237, encodeId=c672195123eae, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Nov 13 04:23:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066326, encodeId=5d852066326ad, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Fri Aug 02 13:23:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514289, encodeId=ee87151428978, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Tue Jan 29 12:23:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359389, encodeId=5b5835938971, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Jan 27 22:26:06 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1951237, encodeId=c672195123eae, content=<a href='/topic/show?id=4f5c322640f' target=_blank style='color:#2F92EE;'>#利什曼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32264, encryptionId=4f5c322640f, topicName=利什曼病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Wed Nov 13 04:23:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066326, encodeId=5d852066326ad, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Fri Aug 02 13:23:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514289, encodeId=ee87151428978, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Tue Jan 29 12:23:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359389, encodeId=5b5835938971, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sun Jan 27 22:26:06 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
    2019-01-27 王秀

    学习了,涨知识了!

    0

相关资讯

Lancet HIV:HIV感染人群肿瘤、心肌梗塞、终末期肝病及肾病风险因素研究

研究认为,HIV感染人群非HIV相关肿瘤、心肌梗塞、终末期肝病及肾病的主要风险因素与一般人群相同,对相应风险因素采取必要的干预措施有助于降低HIV感染人群的并发症风险

JCO:HIV感染对肝癌预后的影响

肝细胞癌(HCC)是HIV患者死亡的主要原因,HIV血清阳性可能会影响肝细胞癌患者的预后。JCO近期发表了一篇文章,研究HIV是否影响HCC患者的总生存(OS)。

Science:揭示先天免疫系统介导的HIV纳米颗粒免疫原靶向生发中心机制

免疫系统能够识别纳米和微米大小的颗粒(比如病毒和细菌)并对它们作出反应。纳米颗粒经输入淋巴被运送到淋巴组织中,经内化和加工后用于树突细胞的抗原呈递,并且通过B细胞受体(BCR)的结合激活B细胞。免疫识别的这些特征促进人们将纳米颗粒抗原用于许可的疫苗中,比如HPV疫苗和乙肝病毒疫苗,并且在开发新疫苗时促进人们设计纳米颗粒形式的免疫原。对HIV病毒而言,来自临床前动物模型的证据表明相比于单体抗原,纳米

PNAS:中疾控合作团队发现同亚型不同簇HIV-1具不同免疫损伤力及其发生机理

中疾控邵一鸣团队早先报道过中国性传播艾滋病起源于泰国CRF01AE亚型的多个流行簇(C1-C8),引起当前艾滋病流行三大病毒簇包括,在异性人群传播的1簇(C1)和男同性恋(MSM)人群传播的4簇和5簇(C4、C5)。

j nat prod:中国学者发现具有抗HIV活性的二萜化合物

暗罗属(学名:Polyalthia)是番荔枝科下的一个属,为乔木或灌木植物。近日,海南师范大学宋小平教授课题组报道从一种海南暗罗的根中分离得到了一些3,4-裂环-降碳的克罗烷型二萜化合物,并研究了它们的抗HIV活性。

NATURE:HIV如何避免先天免疫感知?

在哺乳动物中,RNA的2'-O-甲基化是一个重要的分子特征,通过该分子特征,细胞先天免疫系统得以区分内源性和外源性信使RNA。

Baidu
map
Baidu
map
Baidu
map